Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.10, $0.08 better than the analyst estimate of $0.02. Revenue for the quarter came in at $67.77 million versus the consensus estimate of $57.48 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Rigetti Computing (RGTI) call put ratio 10.4 calls to 1 put with a focus on June 26 weekly 25 calls as share price up 2.8%
• FedEx (FDX) call put ratio 1 call to 2.8 puts with a focus on June 26 weekly 325 puts into quarter results